Education
About Us
Working with TipRanks
Follow Us
Enzolytics (ENZC)
:ENZC
ENZC Stock Chart & Stats
$0.01
>-$0.01(-4.55%)
At close: 4:00 PM EST
$0.01
>-$0.01(-4.55%)
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
Volume3.47M
Average Volume (3M)N/A
Market Cap
$1.18M
Enterprise ValueN/A
Total Cash (Recent Filing)$200.00M
Total Debt (Recent Filing)$996.34K
Price to Earnings (P/E)―
Beta0.43
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding3,941,644,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-0.01
Price to Sales (P/S)0.00
P/FCF Ratio-2.18
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ENZC FAQ
What was Enzolytics’s price range in the past 12 months?
Currently, no data Available
What is Enzolytics’s market cap?
Enzolytics’s market cap is $1.18M.
When is Enzolytics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Enzolytics’s earnings last quarter?
Currently, no data Available
Is Enzolytics overvalued?
According to Wall Street analysts Enzolytics’s price is currently Overvalued.
Does Enzolytics pay dividends?
Enzolytics does not currently pay dividends.
What is Enzolytics’s EPS estimate?
Enzolytics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enzolytics have?
Enzolytics has 3,941,644,000 shares outstanding.
What happened to Enzolytics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Enzolytics?
Currently, no hedge funds are holding shares in ENZC
Company Description
Enzolytics
Enzolytics, Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, it has created a proprietary cell line that produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics Inc. is based in Plano, Texas.
Scinai Immunotherapeutics
―
Aditxt
―
MSP Recovery
―
CERo Therapeutics Holdings
―
Conduit Pharmaceuticals
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.05% Other Institutional Investors
99.95% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---